However, the inability of checkpoint inhibitors to show efficacy against tumors not expressing PD-L1 [50] has limited their efficacy in the setting of breast cancer; for example, up to 70% of women with triple-negative breast cancer have tumors expressing low levels of PD-L1 [51]. The gene discussed is CD274; the disease is breast cancer.